Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

185.16 +2.99 (+1.64%)
Official Closing Price Updated: 7:00 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,948,865
Open 183.45
Bid (Size) 184.60 (2)
Ask (Size) 186.30 (1)
Prev. Close 182.17
Today's Range 182.11 - 186.85
52wk Range 135.85 - 186.85
Shares Outstanding N/A
Dividend Yield 3.20%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AbbVie Wins Analyst Confidence with Q2 Beat, Diverse Portfolio Fuels Long-Term Growth Expectations
AbbVie reports Q2 earnings with adjusted EPS of $2.65, surpassing expectations. Net revenues hit $14.46 billion, reflecting a 4.3% increase. Analysts maintain a positive outlook with increased price... 
Via Benzinga
Lockheed Martin To Rally Over 14%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga

Performance

YTD
+15.86%
+15.86%
1 Month
+8.44%
+8.44%
3 Month
+10.68%
+10.68%
6 Month
+12.13%
+12.13%
1 Year
+30.49%
+30.49%

More News

Read More
Why AbbVie Stock Was Cruising Higher on Thursday
Via The Motley Fool
AbbVie (ABBV) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Peeling Back The Layers: Exploring AbbVie Through Analyst Insights
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today
Via Benzinga
AbbVie Unusual Options Activity
Via Benzinga
Stocks Rebound As US Economy Flexes Muscles, Small Caps Rally, Gold Falls: What's Driving Markets Thursday?
Via Benzinga
Topics Economy
Exposures Economy
AbbVie Stock News: Why ABBV Is the Top Trending Ticker Today
Via InvestorPlace
AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs
Via Benzinga
Topics Earnings
Exposures Financial
AbbVie Slides Despite Beating Second-Quarter Views, Raising Guidance
Via Investor's Business Daily
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
Via FinancialNewsMedia
Exposures Product Safety
Is AbbVie the Best Dividend Stock for You?
Via The Motley Fool
7 Trustworthy Dividend Stocks to Steadily Build Your Portfolio
Via InvestorPlace
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
From FN Media Group LLC
Via GlobeNewswire
AbbVie Earnings Preview: Will Humira's Expiry, New CEO Fuel A Bullish Surge?
Via Benzinga
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?
Via The Motley Fool
Nasdaq, S&P Futures Slide On More Negative Tech Tidings As Focus Shifts To Q2 GDP Data: Strategist Says Trump Trades May Not Work Even If Ex-President Retakes White House
Via Benzinga
Topics Government Stocks
Exposures Political US Equities
10 Best Dividend Growth Stocks to Buy and Hold Forever
Via The Motley Fool
7 High-Yield Dividend Stocks to Help Pay Your Bills
Via InvestorPlace
Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally
Via Benzinga
3 Absurdly Cheap Stocks to Buy and Hold for Years
Via The Motley Fool
7 High-Yield Dividend Stocks Beating Inflation
Via InvestorPlace
Topics Economy
Exposures Interest Rates
3 Quantum AI Stocks That Could Redefine Computing
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.